Rift valley fever medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Rift valley fever}}
{{Rift valley fever}}
{{CMG}}{{AE}} {{AAH}}
{{CMG}}{{AE}} {{AAH}}
==Overview==
===Medical Therapy===
===Medical Therapy===
*Mainstay of treatment in most RVF patients is usually supportive with monitoring of body temperature and [[Blood pressure|blood pressure]].
*Mainstay of treatment in most RVF patients is usually supportive with monitoring of body temperature and [[Blood pressure|blood pressure]].

Revision as of 03:48, 17 July 2021

Rift valley fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Rift valley fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rift valley fever medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rift valley fever medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rift valley fever medical therapy

CDC on Rift valley fever medical therapy

Rift valley fever medical therapy in the news

Blogs on Rift valley fever medical therapy

Directions to Hospitals Treating Rift valley fever

Risk calculators and risk factors for Rift valley fever medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aakash Hans, MD[2]

Overview

Medical Therapy

  • Mainstay of treatment in most RVF patients is usually supportive with monitoring of body temperature and blood pressure.
  • Fluids may be given to patients reporting weakness or low blood pressure.
  • There is no specific recommendations for treatment for RVF by the FDA. [1]
  • Drugs having renal, hepatic or coagulation side effects should be avoided in RVF patients.
  • Ribavirin showed promise in rodent models but was stopped after development of neurological symptoms in some of the patients it was administered during the RVF outbreak in Saudi Arabia in the year 2000. [2]

Surgical Therapy

The mainstay of treatment for RVF is medical therapy. Surgery is usually not required in such cases.

Pharmacotherapy

Studies in monkeys and other animals have shown promise for ribavirin, an antiviral drug, for future use in humans. Additional studies suggest that interferon, immune modulators, and convalescent-phase plasma may also help in the treatment of patients with RVF.

References

  1. Hartman A. Rift Valley Fever. Clin Lab Med. 2017;37(2):285-301. doi:10.1016/j.cll.2017.01.004
  2. Bird BH, Reynes JM, Nichol ST. Rift Valley Fever. In: Magill AJ, Strickland GT, Maguire JH, Ryan ET, Solomon T, editors. Hunter’s Tropical Medicine and Emerging Infectious Disease. 9. Elsevier Health Sciences; 2012.

Template:WH Template:WS